Articles from Palleon Pharmaceuticals

Palleon Pharmaceuticals, a company developing sialoglycan degradation as a therapy to treat autoimmune diseases and cancer, today announced two upcoming poster presentations at key autoimmune disease medical conferences. Together, the presentations provide insight into HLX79/E-602, a first-in-class human sialidase enzyme therapeutic, and its application in addressing autoimmune diseases through targeting cell surface sugars.

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced the first patient has been dosed in the Phase 2 clinical trial of Palleon’s potential first-in-class human sialidase enzyme therapeutic E-602 (HLX79) in combination with Henlius’ self-developed HANLIKANG (rituximab biosimilar) in patients with active glomerulonephritis, a form of autoimmune kidney disease that includes membranous nephropathy (MN) and lupus nephritis (LN). The Phase 2 clinical trial is being conducted in mainland China.

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced that the China National Medical Products Administration (NMPA) has cleared Shanghai Henlius Biotech’s Investigational New Drug (IND) application for a Phase 2 clinical trial of Palleon’s first-in-class human sialidase enzyme therapeutic, E-602 (HLX79), in combination with Henlius’ self-developed HANLIKANG (rituximab biosimilar) in patients with active glomerulonephritis, including lupus nephritis (LN). With this clearance, Henlius will initiate the first clinical trial of Palleon’s glyco-immunology platform in autoimmune diseases.

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN).

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602, its first-in-class human sialidase enzyme therapeutic, in combination with PD-1 inhibitor cemiplimab (Libtayo®) in patients with PD-(L)1-resistant solid tumors. The results will be shared in both rapid oral and poster presentations on Saturday, November 9 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, Texas.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present new findings from a study leveraging its HYDRA platform that suggests a link between stromal hypersialylation and immunosuppression activity within the colorectal tumor microenvironment at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place in San Diego from November 1-5, 2023.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that Fierce Biotech has recognized the company as one of its “Fierce 15” for 2023. This annual report features the most innovative and promising biotechnology companies in the industry.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform. The GLIMMER-01 (Glycan-Mediated Immune Regulation) trial is designed to study E-602 as a monotherapy and in combination with cemiplimab (anti-PD-1) in patients with advanced cancers.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced the initial Phase 1 results from the GLIMMER-01 trial of its lead EAGLE oncology platform program, E-602, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company will present at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023. Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon, will present as part of the private company track at 2:10 p.m. EST at the St. Regis New York hotel, and Palleon will participate in 1x1 investor meetings during the event.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No.11,459,398 titled, “Conjugates for Targeted Cell Surface Editing.” The patent broadens Palleon’s intellectual property position and bolsters coverage for the company’s proprietary EAGLE platform, which is based on engineered human sialidase enzymes that restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and across immune cell types.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022. Jim Broderick, M.D., Chief Executive Officer and founder of Palleon, will present a company overview at 11:45am PT and Palleon will host 1x1 investor meetings, which can be requested through Oppenheimer.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer’s 37th Annual Meeting taking place in Boston from November 8-12, 2022. E-602 Bi-Sialidase is a first-in-class, glyco-immune checkpoint inhibitor which restores anti-tumor immunity by enzymatically degrading immunosuppressive sialoglycans in hypersialylated tumors and immune cells.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company’s scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry. This commendation reflects Dr. Bertozzi’s deep contributions not only to chemistry but to biology and medicine, including the foundational science underlying Palleon’s first-in-class, clinical-stage therapeutic platform.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced a strategic collaboration with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize two bifunctional sialidase programs from Palleon’s EAGLE (Enzyme-Antibody Glyco-Ligand Editing) immuno-oncology platform, including Palleon’s Bifunctional HER2-Sialidase now in preclinical development and a second bifunctional sialidase to be developed with a proprietary target provided by Henlius.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today presented new preclinical data on the company’s lead oncology program, E-602, as well as data supporting Palleon’s novel bifunctional PD-L1-Targeted Sialidase, in two poster presentations at the American Association for Cancer Research Annual Meeting in New Orleans, La.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug (IND) application for its lead candidate E-602. This clearance paves the way for Palleon’s first-in-class cancer immunotherapy which targets immunosuppressive sialoglycans to enter clinical testing.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of Denis Patrick, Ph.D., to its Board of Directors. Dr. Patrick is Vice President and Head of Partnering Innovation at Pfizer and a Managing Partner at Pfizer Ventures, the venture capital arm of Pfizer Inc.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today presented data on a novel mechanism of action of the company’s EAGLE sialoglycan degradation therapeutic platform. Preclinical studies, presented in a poster at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), show that EAGLE therapeutic candidates’ desialylation of T cells enhances T cell anti-tumor immunity, and that lead candidate E-602 (Bi-Sialidase) is efficacious and safe in animal models.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of David Johnson as an independent director to its Board of Directors. Mr. Johnson most recently served as Chief Executive Officer and Founder of VelosBio prior to its acquisition by Merck.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. Dr. Feltquate is an accomplished development leader with significant industry experience in immuno-oncology clinical development, translational medicine, and diagnostic assay advancement.

Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the presentation of data supporting the role of hypersialylation in the immune escape of metastatic melanoma at the AACR Annual Meeting held virtually April 10-15, 2021.